News All PostNewsALZHEIMER’S DRUG DISCOVERY FOUNDATION AND AXXAM CONTINUE THEIR SUCCESSFUL COLLABORATION TO DEVELOP NOVEL THERAPEUTICS FOR ALZHEIMER’S DISEASE17 December 2014read more >Axxam and F.Hoffman La Roche Ltd enter into research collaboration21 November 2014read more >BANDO DI SELEZIONE PER LA PARTECIPAZIONE AL PROGETTO DI FORMAZIONE CTN01_00177_96286520 November 2014read more >Axxam launches the ion channel-FLASH technology based on light mediated activation of voltage-gated ion channels23 April 2014read more >Axxam and Cellectis bioresearch announce their collaboration to offer a new generation of cell-based assays20 January 2014read more >Hit Discovery Constance GmbH: a new European hub for HTS and compound management13 January 2014read more >Load MoreEnd of Content.
ALZHEIMER’S DRUG DISCOVERY FOUNDATION AND AXXAM CONTINUE THEIR SUCCESSFUL COLLABORATION TO DEVELOP NOVEL THERAPEUTICS FOR ALZHEIMER’S DISEASE17 December 2014read more >
BANDO DI SELEZIONE PER LA PARTECIPAZIONE AL PROGETTO DI FORMAZIONE CTN01_00177_96286520 November 2014read more >
Axxam launches the ion channel-FLASH technology based on light mediated activation of voltage-gated ion channels23 April 2014read more >
Axxam and Cellectis bioresearch announce their collaboration to offer a new generation of cell-based assays20 January 2014read more >
Hit Discovery Constance GmbH: a new European hub for HTS and compound management13 January 2014read more >